Intellia Therapeutics (NTLA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
FDA accepted the lonvo-z BLA for Priority Review, set a March 10, 2027 PDUFA date and is not currently planning an advisory committee meeting.
HAELO Phase 3 met its primary and key secondary endpoints: attacks fell 87% vs. placebo, 62% were attack-free and therapy-free vs. 11%, and no serious adverse events occurred in the lonvo-z arm.
Nex-z Phase 3 studies resumed after FDA holds were lifted; MAGNITUDE-2 enrollment was completed, and MAGNITUDE enrollment continued.
Q1 2027 U.S. launch preparation advanced, including deployment of a field organization and engagement with HAE centers and payers, subject to approval.
Financial highlights
Q3 collaboration revenue was $7.2M vs. $13.8M, primarily reflecting lower Regeneron revenue; 9M revenue was $29.9M vs. $44.7M, also affected by lower material shipments and a 2025 hemophilia B milestone.
Q3 R&D expense was $83.3M vs. $94.7M; lower lonvo-z external costs, stock-based compensation and research costs were partly offset by higher headcount expense.
Q3 G&A rose to $46.1M from $30.5M, driven by commercial infrastructure, legal, facility and compensation costs; 9M G&A rose $32.1M to $118.8M.
Q3 operating expenses were $129.5M vs. $125.3M; operating loss was $122.3M vs. $111.5M and net loss was $127.5M vs. $101.3M.
9M operating expenses fell to $365.5M from $386.9M and operating loss narrowed to $335.6M from $342.3M, while net loss widened to $330.4M from $316.9M.
Outlook and guidance
Cash, cash equivalents and marketable securities of $614.8M at Sept. 30, 2026 are expected to fund operating expenses and capital needs at least into 2028; guidance excludes potential lonvo-z revenue, milestone payments and strategic uses.
2026 R&D expense is expected to decrease as resources focus on lonvo-z and nex-z, mostly offset by commercial infrastructure spending.
Planned lonvo-z U.S. launch is in Q1 2027, subject to FDA approval; readiness work is on track ahead of the PDUFA date.
Latest events from Intellia Therapeutics
- Lonvo-z approaches a 2027 decision as launch planning and TTR trials advance.NTLA
Jefferies Global Healthcare Conference - Lonvo-z showed durable HAE control as FDA review and launch preparations advance.NTLA
Study update - Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects.NTLA
Morgan Stanley 24th Annual Global Healthcare Conference - Strong Phase 3 data and $628.4M cash position support launch plans and ongoing clinical progress.NTLA
Q2 2026 - Accelerated phase III progress in ATTR and HAE, with major data and milestones expected by 2027.NTLA
BofA Securities 2025 Healthcare Conference - Nexi/nex-z achieved deep, durable TTR reduction and clinical stabilization in ATTR amyloidosis.NTLA
Study Update - Strong CRISPR trial progress, $944.7M cash, Q3 net loss $135.7M, late-stage pipeline advancing.NTLA
Q3 2024 - A single 50 mg dose achieved 81% attack reduction and 73% attack-free rate in HAE patients.NTLA
Study Update - Late-stage pipeline progress, restructuring, and cash runway extend operational momentum into 2027.NTLA
Q4 2024